Nano-X Imaging Ltd.

Analysis for Ticker: NNOX

Nano-X Imaging Ltd is a medical technology entity based in Israel that claims to democratize diagnostic imaging through digital X-ray sources and artificial intelligence analysis. The internal numbers reveal a structure that does not generate capital but merely harvests it from investors to fund a deficit that has reached 378,7$ million. In 2024, the business spent 21,9$ million to generate only 11,3$ million in sales, creating a gross loss of 10,6$ million before it even pays its executives. For a child to understand, imagine a lemonade stand where the lemons and sugar cost ten dollars but the child only sells the juice for five dollars; no matter how many cups are sold, the child will always be poorer until someone else gives them more money to keep the stand open. The mechanism of survival began with a share count of 51,8 million at the start of 2022. Management incinerated tens of millions on acquisitions like VasoHealthcare IT and USARAD, only to later admit the value was gone by recording impairments of 50,8$ million in 2022 and 7,4$ million in 2023. By the end of 2024, the company had printed and sold five million new shares to the public to cover a 36,4$ million operating cash hemorrhage. While the business lost 53,5$ million that year, the chief executive drew a 900.000$ base salary and the top five executives absorbed over 5,6$ million in total compensation.